Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Date Issued
2023-09-05
Author(s)
André, F
Su, F
Solovieff, N
Hortobagyi, G
Chia, S
Neven, P
Bardia, A
Tripathy, D
Lteif, A
Taran, T
Babbar, N
Slamon, D
Arteaga, C L
Abstract
The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Using the largest pooled biomarker dataset of the CDK4/6 inhibitor ribociclib in ABC to date, we identified potential biomarkers of response to ribociclib.
Subjects
CDK4/6 inhibitor; advanced breast cancer; biomarkers; progression-free survival; ribociclib
SDGs
Type
journal article